- Home
- OPT vs PUBM Comparison
OPT vs PUBM Comparison
Compare OPT & PUBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- PUBM
- Stock Information
- Founded
- OPT 1984
- PUBM 2006
- Country
- OPT Australia
- PUBM United States
- Employees
- OPT N/A
- PUBM N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- PUBM Computer Software: Prepackaged Software
- Sector
- OPT Health Care
- PUBM Technology
- Exchange
- OPT Nasdaq
- PUBM Nasdaq
- Market Cap
- OPT 767.9M
- PUBM 724.9M
- IPO Year
- OPT 2020
- PUBM 2020
- Fundamental
- Price
- OPT $3.24
- PUBM $14.88
- Analyst Decision
- OPT Strong Buy
- PUBM Buy
- Analyst Count
- OPT 1
- PUBM 7
- Target Price
- OPT $12.00
- PUBM $21.17
- AVG Volume (30 Days)
- OPT 39.0K
- PUBM 386.8K
- Earning Date
- OPT 08-30-2024
- PUBM 11-12-2024
- Dividend Yield
- OPT N/A
- PUBM N/A
- EPS Growth
- OPT N/A
- PUBM 553.89
- EPS
- OPT N/A
- PUBM 0.32
- Revenue
- OPT $261,859.00
- PUBM $290,354,000.00
- Revenue This Year
- OPT N/A
- PUBM $10.76
- Revenue Next Year
- OPT $46,864.64
- PUBM $9.74
- P/E Ratio
- OPT N/A
- PUBM $46.35
- Revenue Growth
- OPT N/A
- PUBM 13.11
- 52 Week Low
- OPT $1.79
- PUBM $13.18
- 52 Week High
- OPT $5.45
- PUBM $25.36
- Technical
- Relative Strength Index (RSI)
- OPT 27.29
- PUBM 44.86
- Support Level
- OPT $4.02
- PUBM $15.20
- Resistance Level
- OPT $4.18
- PUBM $17.74
- Average True Range (ATR)
- OPT 0.22
- PUBM 0.66
- MACD
- OPT -0.13
- PUBM 0.02
- Stochastic Oscillator
- OPT 6.85
- PUBM 17.10
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
About PUBM PubMatic Inc.
PubMatic is one of the leading supply-side platform providers in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, better manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). PubMatic generates revenue mainly via taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Given the growth in overall digital advertising, more publishers and advertisers are adopting programmatic (or automated) buying and selling, driving the firm's success in attracting more inventory.